NL-OMON34049招募中2 期
Autophagy inhibition using hydrochloroquine in breast cancer patients: a pilot study - HCQ TRIA
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients with core-biopsy proven invasive adenocarcinoma of the breast
- •Any tumor with a size >= 1cm (NOT inflammatory breast cancer)
- •WHO-performance score 0 or 1
- •Written informed consent
排除标准
- •Any psychological, familial, sociological or geographical condition potentially hampering adequate informed consent or compliance with the study protocol
- •Hampered liver or kidney function
- •Serious gastro-intestinal disease
- •Neurological disease (including epilepsy)
- •Hematological disease
- •G6PD deficiency
- •Hypersensitivity for quinine
- •Use of gold containing drugs, oxyfenbutazone, fenylbutazone, digoxin
- •Operation for breast cancer foreseen within 14 days after inclusion in the study.
研究者
相似试验
进行中（未招募）
1 期
Autophagy inhibition using hydrochloroquine in breast cancer patients: a pilot study - HCQ TRIAEUCTR2010-022842-26-NLniversity Medical Centre Nijmegen20
进行中（未招募）
不适用
Treatment with hydroxychloroquine and erlotinib in patients with non-small-cell lung cancerPatients with histologically confirmed stage IV non-squamous non-small-cell lung cancer (NSCLC)• with an activating EGFR mutation who progressed on erlotinib or gefitinib monotherapy. OR• who failed after at least one line of platinum based doublet chemotherapy and who are EGFR TKI naïve.EUCTR2011-004903-20-NL136
已完成
2 期
Hydroxychloroquine as an anti-autophagy and chromatin modulating drug in combination with erlotinib in non-small cell lung cancer (NSCLC) patients: a single-center single arm open-label phase II trialAdvanced stage NSCLCMetastatic NSCLC10038666NL-OMON37508Vrije Universiteit Medisch Centrum136
进行中（未招募）
不适用
Chloroquine as an anti-autophagy drug in small cell lung cancer (SCLC) patients: A phase I trial to be followed by a phase II trial. - chloroquine in SCLCEUCTR2009-014772-22-NLMAASTRO Clinic
已完成
不适用
Hydroxychloroquine and erlotinib in NSCLC.histologically confirmed stage IV non-squamous NSCLC patients who are eligible to start with EGFR targeted therapy1.patients who progressed on erlotinib or gefitinib monotherapy after having experienced an initial response.2.patients who failed chemotherapy after at least one line of platinum based doublet chemotherapy and who are EGFR TKI naïveDutch:Histologisch bewezen stadium IV non-squamous NSCLC patienten.• Patienten:• met een activerende EGFR mutatie die progressief zijn onder erlotinib of gefitinib monotherapie.OF• welke progressieve ziekte hebben na eerdereNL-OMON21406VU University Medical Center136